Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.
Type:
Grant
Filed:
November 25, 2020
Date of Patent:
October 17, 2023
Assignee:
AICURIS ANTI-INFECTIVE CURES AG
Inventors:
Wilfried Schwab, Alexander Birkmann, Kerstin Paulus, Kurt Vogtli, Dieter Haag, Stephan Maas, Kristian Ruepp